Analyst Price Target is $44.83
▲ +29.20% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Belite Bio in the last 3 months. The average price target is $44.83, with a high forecast of $60.00 and a low forecast of $25.00. The average price target represents a 29.20% upside from the last price of $34.70.
Current Consensus is
Buy
The current consensus among 7 investment analysts is to buy stock in Belite Bio. This Buy consensus rating has held steady for over two years.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Read More